FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231527618> ?p ?o ?g. }

• W4231527618 endingPage "CT128" @default.
• W4231527618 startingPage "CT128" @default.
• W4231527618 abstract "Abstract Background: Addition of the cyclin dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib to endocrine therapy significantly improves progression free survival (PFS) in patients with HR+ MBC. The primary toxicity is neutropenia (ntp). TBCRC035 explored rates of neutropenia in patients with prior chemotherapy for MBC with 2 dose levels of palbociclib, and correlated changes in retinoblastoma protein phosphorylation (pRB) and Ki67 expression in proliferating keratinocytes and tumor, as well as mutations in cell-free DNA (cfDNA) with response. Methods: TBCRC035 is a 1:1 randomized multicenter Phase II study evaluating palbociclib at either 125 or 100 mg in combination with physician choice fulvestrant or tamoxifen. Eligible patients (pts) with HR+ MBC had received 1-3 lines of chemotherapy for MBC, any number of hormone therapies, and were naïve to CDK4/6i. The primary endpoint was grade 3/4 ntp; secondary endpoints included PFS, clinical benefit rate (CBR), safety/tolerability, inhibition of RB phosphorylation (pRB) and change in Ki67 expression in skin and tumor (FFPE sections of skin and tumor biopsies) at day 14-21 of treatment compared to baseline, and correlation of response with mutations in cell free DNA (cfDNA). FFPE sections of skin punch and tumor biopsies were stained using antibodies to Ki67, total RB, and phospho-RB-S780 using BOND polymer red detection. Stained slides were scanned into the Aperio image analysis platform; the percentage of marker positive cells was determined. Whole blood was collected at baseline & processed for plasma; cfDNA was extracted. Using a combination of digital PCR and ultradeep next generation sequencing, cfDNA was analyzed for ESR1 and PIK3CA mutations. Results: 70 pts were enrolled; 35 were randomized to 100 vs 125 mg of palbociclib respectively. 12 pts (100 mg), and 19 pts (125 mg) had &gt;1 episode of grade 3/4 ntp (p=0.091). Pts on 100 mg had fewer total episodes of grade 3/4 ntp (p=0.036). Dose reductions were more frequent in patients starting with 125 mg compared to those starting with 100 mg (12 vs6). CBR and PFS were similar (100 vs 125 mg; CBR: 67 vs 74%; PFS: 6.5 vs 10 mo,p=0.18). In skin and tumor, the % of Ki67-positive nuclei was significantly lower in post-treatment biopsies (p&lt;0.0001 for both) and was similarly reduced for pRb in skin, (tumor data pending); there was no significant difference in % change in pRB and Ki67 by palbociclib dose, or by CBR or PFS. Higher baseline tumor Ki67 was associated with worse PFS (p=0.006), regardless of dose. Presence of PIK3CA mutations in cfDNA correlated with worse PFS (p=0.008), but ESR1 mutations did not. Conclusion: In pts with prior chemotherapy for HR+ MBC, treatment with 100 mg of palbociclib significantly reduced episodes of ntp and dose reductions; efficacy was comparable to patients treated with 125mg. Reductions in expression of Ki67 in tumor and keratinocytes and pRB in keratinocytes were comparable between dose levels indicating robust inhibition of CDK4/6 at both doses. The presence of PIK3CA mutations correlated with reduced PFS. These data suggest that dose reduction of palbociclib to mitigate toxicity should not compromise efficacy and provide additional prognostic information for use in treatment selection. Citation Format: Hope S. Rugo, Erica Mayer, Anna Maria Storniolo, Claudine Isaacs, Ingrid Mayer, Vered Stearns, Rita Nanda, Julie Nangia, Michelle Melisko, Chiara Wabl, Alona Muzikansky, Bose Kochupurakkal, Ben H. Park, Antonio Wolff, Geoffrey Shapiro. Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT128." @default.
• W4231527618 created "2022-05-12" @default.
• W4231527618 creator A5000761973 @default.
• W4231527618 creator A5005007467 @default.
• W4231527618 creator A5007261291 @default.
• W4231527618 creator A5013091949 @default.
• W4231527618 creator A5026024346 @default.
• W4231527618 creator A5045419282 @default.
• W4231527618 creator A5046515010 @default.
• W4231527618 creator A5053390874 @default.
• W4231527618 creator A5056530735 @default.
• W4231527618 creator A5069182089 @default.
• W4231527618 creator A5071176191 @default.
• W4231527618 creator A5073728088 @default.
• W4231527618 creator A5088192892 @default.
• W4231527618 creator A5090188675 @default.
• W4231527618 creator A5091723009 @default.
• W4231527618 date "2019-07-01" @default.
• W4231527618 modified "2023-10-16" @default.
• W4231527618 title "Abstract CT128: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers" @default.
• W4231527618 doi "https://doi.org/10.1158/1538-7445.am2019-ct128" @default.
• W4231527618 hasPublicationYear "2019" @default.
• W4231527618 type Work @default.
• W4231527618 citedByCount "1" @default.
• W4231527618 countsByYear W42315276182021 @default.
• W4231527618 crossrefType "journal-article" @default.
• W4231527618 hasAuthorship W4231527618A5000761973 @default.
• W4231527618 hasAuthorship W4231527618A5005007467 @default.
• W4231527618 hasAuthorship W4231527618A5007261291 @default.
• W4231527618 hasAuthorship W4231527618A5013091949 @default.
• W4231527618 hasAuthorship W4231527618A5026024346 @default.
• W4231527618 hasAuthorship W4231527618A5045419282 @default.
• W4231527618 hasAuthorship W4231527618A5046515010 @default.
• W4231527618 hasAuthorship W4231527618A5053390874 @default.
• W4231527618 hasAuthorship W4231527618A5056530735 @default.
• W4231527618 hasAuthorship W4231527618A5069182089 @default.
• W4231527618 hasAuthorship W4231527618A5071176191 @default.
• W4231527618 hasAuthorship W4231527618A5073728088 @default.
• W4231527618 hasAuthorship W4231527618A5088192892 @default.
• W4231527618 hasAuthorship W4231527618A5090188675 @default.
• W4231527618 hasAuthorship W4231527618A5091723009 @default.
• W4231527618 hasConcept C121608353 @default.
• W4231527618 hasConcept C126322002 @default.
• W4231527618 hasConcept C143998085 @default.
• W4231527618 hasConcept C197934379 @default.
• W4231527618 hasConcept C203092338 @default.
• W4231527618 hasConcept C2775930923 @default.
• W4231527618 hasConcept C2776694085 @default.
• W4231527618 hasConcept C2777063308 @default.
• W4231527618 hasConcept C2777176818 @default.
• W4231527618 hasConcept C2778375690 @default.
• W4231527618 hasConcept C2779744173 @default.
• W4231527618 hasConcept C2779984678 @default.
• W4231527618 hasConcept C2780482068 @default.
• W4231527618 hasConcept C31760486 @default.
• W4231527618 hasConcept C530470458 @default.
• W4231527618 hasConcept C535046627 @default.
• W4231527618 hasConcept C71924100 @default.
• W4231527618 hasConceptScore W4231527618C121608353 @default.
• W4231527618 hasConceptScore W4231527618C126322002 @default.
• W4231527618 hasConceptScore W4231527618C143998085 @default.
• W4231527618 hasConceptScore W4231527618C197934379 @default.
• W4231527618 hasConceptScore W4231527618C203092338 @default.
• W4231527618 hasConceptScore W4231527618C2775930923 @default.
• W4231527618 hasConceptScore W4231527618C2776694085 @default.
• W4231527618 hasConceptScore W4231527618C2777063308 @default.
• W4231527618 hasConceptScore W4231527618C2777176818 @default.
• W4231527618 hasConceptScore W4231527618C2778375690 @default.
• W4231527618 hasConceptScore W4231527618C2779744173 @default.
• W4231527618 hasConceptScore W4231527618C2779984678 @default.
• W4231527618 hasConceptScore W4231527618C2780482068 @default.
• W4231527618 hasConceptScore W4231527618C31760486 @default.
• W4231527618 hasConceptScore W4231527618C530470458 @default.
• W4231527618 hasConceptScore W4231527618C535046627 @default.
• W4231527618 hasConceptScore W4231527618C71924100 @default.
• W4231527618 hasIssue "13_Supplement" @default.
• W4231527618 hasLocation W42315276181 @default.
• W4231527618 hasOpenAccess W4231527618 @default.
• W4231527618 hasPrimaryLocation W42315276181 @default.
• W4231527618 hasRelatedWork W1982876272 @default.
• W4231527618 hasRelatedWork W2092789082 @default.
• W4231527618 hasRelatedWork W2593892593 @default.
• W4231527618 hasRelatedWork W2944294338 @default.
• W4231527618 hasRelatedWork W2962497808 @default.
• W4231527618 hasRelatedWork W3139237627 @default.
• W4231527618 hasRelatedWork W3168048632 @default.
• W4231527618 hasRelatedWork W4220872882 @default.
• W4231527618 hasRelatedWork W4281734929 @default.
• W4231527618 hasRelatedWork W4323050407 @default.
• W4231527618 hasVolume "79" @default.
• W4231527618 isParatext "false" @default.
• W4231527618 isRetracted "false" @default.
• W4231527618 workType "article" @default.